ABSTRACT
The toxicity of acyclovir (ACV) produced by Lachema, Brno was compared with that of Zovirax, Wellcome. The in vitro suppressive effect of both substances was found equal and concentration dependent. The primary humoral antibody response was more sensitive to ACV than the cellular (blast transformation) response. However, spleen cells of drug-treated mice (either with the domestic compounds or Wellcome origin) differed neither in blast transformation test nor in the secretory antibody response. None of the drugs when given in adequate therapeutic dose did significantly influence the cell mediated response or antibody formation by spleen cells. Summing up, the acute immunotoxicity of both compounds was low; in this respect acyclovir Lachema did not differ from Zovirax Wellcome.
Subject(s)
Acyclovir/pharmacology , Antibody Formation/drug effects , Immunity, Cellular/drug effects , Animals , Cells, Cultured , Hypersensitivity, Delayed/immunology , In Vitro Techniques , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred CBA , Spleen/cytologyABSTRACT
The effect of oxoplatinum on blastic transformation of human peripheral blood mononuclear cells (PBMC) was monitored following phytohemagglutinin (PHA) stimulation. The results were compared with those published in part III of the present work as well as with the effect of cisplatinum and carboplatinum on the blastic transformation of human cells. In addition, the influence of three Pt-cytostatics on blastic transformation (BT) of PHA pretreated murine splenic cells was studied, and a comparison of sensitivity to cytostatics was made between the murine splenic and human peripheral cells. Cisplatinum demonstrated the highest toxicity, and carboplatinum showed minimum toxicity. The highest inhibitory effect was noted when cytostatics were applied either simultaneously with, or 48 h after PHA, i.e., at the stage of maximum proliferating activity. The murine spleen cells showed higher susceptibility to the effect of Pt-cytostatics in blastic transformation test than human peripheral cells. The murine spleen nuclear cells revealed deeper BT inhibition at the same concentration of substance than the human PBMC.
Subject(s)
Blast Crisis/drug therapy , Cisplatin/therapeutic use , Monocytes/drug effects , Animals , Carboplatin/therapeutic use , Cell Survival/drug effects , Cisplatin/analogs & derivatives , Female , Humans , Mice , Mice, Inbred C3H , Monocytes/immunology , Phytohemagglutinins/pharmacology , Spleen/drug effects , Spleen/immunologyABSTRACT
The present paper investigated the proliferative response of murine splenic cells in the tissue culture after stimulation with the polyclonal activators PHA, ConA and PWM. Proliferation of cells and DNA synthesis were measured by means of radioactively labelled thymidine. Furthermore, the primary antibody response of murine splenic cells in the tissue culture after activation with sheep red blood cells was examined. The response was measured by determining the number of plaque forming cells (PFC). The number of PFC's was determined by the plaque method of local haemolysis, in modification by the drop method. In these tests the ergot alkaloids dihydroergocornine, dihydroergocristine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine were evaluated in two doses, 600 and 1200 micrograms/kg/day p. o. for the period of 14 days. Dihydroergocornine in these tests increased the primary antibody response in a statistically significant manner; on the other hand, after its administration in the higher dose decreased proliferation after PHA was found. The finding after dihydroergocristine administration was of interest. This ergot alkaloid slightly increased proliferation of cells after PHA and PWM as well as the primary antibody response of murine cells. After the administration of dihydro-alpha-ergocryptine increased proliferation after stimulation with PWM and increased primary antibody response, and after the administration of dihydro-beta-ergocryptine increased proliferation of cells after stimulation with PHA were found.
